CAJ | 학술논문

目的评估改良的Hyper-CVAD/MA强化方案治疗侵袭性淋巴瘤患者的有效性和安全性.方法回顾性分析2006年6月至2012年7月收治的42例用改良Hyper-CVAD/MA方案治疗的初治或复治的侵袭性淋巴瘤患者的有效性和安全性.结果 19例(45.3％)患者达完全缓解(CR),13例(31.0％)达部分缓解(PR),有效率为76.2％(32/42).1年无病生存(DFS)率和总体生存(OS)率分别为79.2％和83.7％,3年DFS率和OS率分别为65.3％和64.2％.CR率与有无B症状、结外受累、中枢神经系统受累、Ann Arbor分期、既往治疗有相关性.主要不良反应包括造血功能受抑、感染、黏膜炎、肝脏、肾脏以及神经系统毒性等.结论改良Hyper-CVAD/MA方案治疗侵袭性淋巴瘤近期疗效满意,治疗相关不良反应可以控制.
목적 평고개량적Hyper-CVAD/MA강화방안치료침습성림파류환자적유효성화안전성.방법 회고성분석2006년6월지2012년7월수치적42례용개량Hyper-CVAD/MA방안치료적초치혹복치적침습성림파류환자적유효성화안전성.결과 19례(45.3％)환자체완전완해(CR),13례(31.0％)체부분완해(PR),유효솔위76.2％(32/42).1년무병생존(DFS)솔화총체생존(OS)솔분별위79.2％화83.7％,3년DFS솔화OS솔분별위65.3％화64.2％.CR솔여유무B증상、결외수루、중추신경계통수루、Ann Arbor분기、기왕치료유상관성.주요불량반응포괄조혈공능수억、감염、점막염、간장、신장이급신경계통독성등.결론 개량Hyper-CVAD/MA방안치료침습성림파류근기료효만의,치료상관불량반응가이공제.
Objective To evaluate the efficacy and safety of the modified Hyper-CVAD/MA regimen on patients with invasive non-Hodgkin lymphoma (NHL).Methods Clinical data of 42 invasive NHL patients treated with modified Hyper-CVAD/MA regimen from June 2006 to July 2012 were retrospectively analyzed.Results 19 patients (45.3 ％) got complete response (CR) and 13 patients (31.0 ％) got partial response (PR),with response rate as 76.2 ％ (32/42).The 1-year disease free survival (DFS) rate and overall survival (OS) rate were 79.2 ％ and 83.7 ％ respectively,and those for 3-year were 65.3 ％ and 64.2 ％ respectively.There were poor prognosis and lower CR rate for patients with B system,advanced stage,central nervous system (CNS) and extra-node involved and relapsed.The main adverse reactions were bone marrow suppression,infection,mucositis,and toxicity of liver,kidney and CNS.Conclusion Hyper-CVAD/MA regimen can achieve a satisfactory result in the treatment of invasive NHL patients,and the correlated complications can be controlled.